ES2545736T3 - Aislamiento e identificación de células T - Google Patents
Aislamiento e identificación de células T Download PDFInfo
- Publication number
- ES2545736T3 ES2545736T3 ES10182296.3T ES10182296T ES2545736T3 ES 2545736 T3 ES2545736 T3 ES 2545736T3 ES 10182296 T ES10182296 T ES 10182296T ES 2545736 T3 ES2545736 T3 ES 2545736T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- autoimmune disease
- cell
- composition
- reactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract description 32
- 238000002955 isolation Methods 0.000 title 1
- 229940030156 cell vaccine Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 17
- 208000023275 Autoimmune disease Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 4
- 102000006386 Myelin Proteins Human genes 0.000 description 4
- 108010083674 Myelin Proteins Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- 102000016202 Proteolipids Human genes 0.000 description 2
- 108010010974 Proteolipids Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- VHTZLGUSJUMRPD-LOTBECKMSA-N ENPVVHFFKNIVTPRTP Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C(C)C)C1=CC=CC=C1 VHTZLGUSJUMRPD-LOTBECKMSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 1
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/414—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rehabilitation Therapy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40252102P | 2002-08-08 | 2002-08-08 | |
| US402521P | 2002-08-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2545736T3 true ES2545736T3 (es) | 2015-09-15 |
Family
ID=31715870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10182296.3T Expired - Lifetime ES2545736T3 (es) | 2002-08-08 | 2003-08-06 | Aislamiento e identificación de células T |
| ES03784936.1T Expired - Lifetime ES2537951T3 (es) | 2002-08-08 | 2003-08-06 | Aislamiento e identificación de células T |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03784936.1T Expired - Lifetime ES2537951T3 (es) | 2002-08-08 | 2003-08-06 | Aislamiento e identificación de células T |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7695713B2 (enExample) |
| EP (2) | EP1546719B1 (enExample) |
| JP (2) | JP4705371B2 (enExample) |
| KR (1) | KR100795840B1 (enExample) |
| CN (1) | CN100567987C (enExample) |
| AU (1) | AU2003258090B2 (enExample) |
| BR (1) | BRPI0305769A8 (enExample) |
| CA (2) | CA2492848C (enExample) |
| ES (2) | ES2545736T3 (enExample) |
| IL (1) | IL166332A (enExample) |
| MX (1) | MXPA05001044A (enExample) |
| NO (2) | NO338881B1 (enExample) |
| NZ (1) | NZ537816A (enExample) |
| PL (1) | PL214283B1 (enExample) |
| PT (2) | PT2363710E (enExample) |
| RU (1) | RU2327487C2 (enExample) |
| WO (1) | WO2004015070A2 (enExample) |
| ZA (1) | ZA200500985B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
| EP1546719B1 (en) * | 2002-08-08 | 2015-04-01 | Baylor College Of Medicine | Isolation and identification of t cells |
| EP1824886B1 (en) | 2004-11-17 | 2010-12-22 | Amgen Inc. | Fully human monoclonal antibodies to il-13 |
| WO2007032255A1 (ja) * | 2005-09-13 | 2007-03-22 | Mie University | Ｔ細胞レセプター及び該レセプターをコードする核酸 |
| JP5161798B2 (ja) * | 2006-03-02 | 2013-03-13 | アンチトープ リミテッド | Ｔ細胞アッセイ |
| US9012134B2 (en) | 2006-05-31 | 2015-04-21 | The Regents Of The University Of California | CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ Tregs |
| GB0707933D0 (en) * | 2007-04-24 | 2007-05-30 | Apitope Technology Bristol Ltd | Disease markers |
| US20090062237A1 (en) * | 2007-06-15 | 2009-03-05 | Mayo Foundation For Medical Education And Research | Evaluating immune competence |
| US20110223196A1 (en) * | 2008-11-21 | 2011-09-15 | University Of Miami | Hiv/siv vaccines for the generation of mucosal and systemic immunity |
| US8497071B2 (en) | 2009-06-29 | 2013-07-30 | California Institute Of Technology | Isolation of unknown rearranged T-cell receptors from single cells |
| WO2011080349A1 (en) * | 2010-01-04 | 2011-07-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Detection method of anti-myelin autoreactive t-cells and diagnostic method of autoimmune disease |
| US20130071860A1 (en) * | 2010-02-24 | 2013-03-21 | Matthew B. Hale | Methods for autoimmune disease diagnosis, prognosis, and treatment` |
| DE102011050550A1 (de) * | 2011-05-20 | 2012-11-22 | Wolfgang Göhde | Verfahren und Anordnung zur Quantifizierung von Untergruppen aus einer Mischpopulation von Zellen |
| EP2726879B1 (en) | 2011-07-01 | 2022-10-19 | Beckman Coulter, Inc. | Requlatory t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127 |
| US11782053B2 (en) * | 2011-09-28 | 2023-10-10 | iRepertoire, Inc. | Identification of antigen-specific adaptive immune responses using ARM-PCR and high-throughput sequencing |
| FR2992427A1 (fr) * | 2012-06-20 | 2013-12-27 | Assist Publ Hopitaux De Paris | Methode de pronostic d'un lymphome et kit pour sa mise en oeuvre |
| CA2877933A1 (en) * | 2012-06-27 | 2014-01-03 | Yuri Bushkin | Rapid assays for t-cell activation by rna measurements using flow cytometry |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| JP6508873B2 (ja) * | 2014-01-20 | 2019-05-08 | 国立大学法人富山大学 | 抗原特異的ｔ細胞受容体の取得方法 |
| AU2016315752B2 (en) | 2015-08-31 | 2021-08-05 | Cedars-Sinai Medical Center | Novel blood cell biomarker for late onset Alzheimer's disease |
| JP6830893B2 (ja) * | 2015-09-11 | 2021-02-17 | アステラス製薬株式会社 | 腎前駆細胞を製造する方法 |
| JP7270382B2 (ja) | 2016-05-25 | 2023-05-10 | ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ | 免疫療法の方法 |
| EP3487990A4 (en) * | 2016-06-28 | 2020-07-29 | Geneius Biotechnology, Inc. | T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY |
| EP3570852B1 (en) * | 2017-01-20 | 2025-07-30 | Atara Biotherapeutics, Inc. | Autologous cytotoxic t cells (ctls) expressing an ebv-binding t cell receptor for use in treating or preventing primary progressive multiple sclerosis (ms) or secondary progressive ms |
| JP7193054B2 (ja) * | 2017-06-14 | 2022-12-20 | シンガポール ヘルス サービシズ ピーティーイー． リミテッド | 自己免疫疾患の臨床転帰を評価するための方法及びキット |
| WO2019133793A1 (en) | 2017-12-29 | 2019-07-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Compositions and methods for treating autoimmune disease |
| PL445027A1 (pl) * | 2023-05-29 | 2024-12-02 | Uniwersytet Medyczny w Łodzi | Sposób diagnozowania stwardnienia rozsianego in vitro |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5852225A (ja) | 1981-09-22 | 1983-03-28 | Mitsui Pharmaceut Inc | 脱髄疾患治療剤 |
| US5766920A (en) | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
| US4550086A (en) | 1983-02-16 | 1985-10-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that recognize human T cells |
| IL69686A (en) | 1983-09-11 | 1988-03-31 | Yeda Res & Dev | Compositions containing cell membrane proteins and process for their preparation |
| US4608365A (en) | 1984-03-30 | 1986-08-26 | University Of Southern California | Treatment of neurologic functions |
| US4677061A (en) | 1984-10-19 | 1987-06-30 | Genetic Systems Corporation | T-cell lymphocyte subset monitoring of immunologic disease |
| US4897389A (en) | 1984-10-29 | 1990-01-30 | Chaovanee Aroonsakul | Treating central nervous system diseases |
| US4902680A (en) | 1984-10-29 | 1990-02-20 | Chaovanee Aroonsakul | Treating central nervous system diseases |
| US4898857A (en) | 1984-10-29 | 1990-02-06 | Chaovanee Aroonsakul | Treating control nervous system diseases |
| US4898856A (en) | 1984-10-29 | 1990-02-06 | Chaovanee Aroonsakul | Method for treating central nervous system diseases |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| CA1296622C (en) | 1986-08-12 | 1992-03-03 | Jeffrey E. Anderson | Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system |
| US5849298A (en) | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
| US5039660A (en) | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
| US4902857A (en) * | 1988-12-27 | 1990-02-20 | American Telephone And Telegraph Company, At&T Bell Laboratories | Polymer interconnect structure |
| US5242687A (en) | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
| US6221352B1 (en) | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
| US5612035A (en) * | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| US6007815A (en) | 1989-03-21 | 1999-12-28 | The Immune Response Corporation | Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| US5837246A (en) | 1989-03-21 | 1998-11-17 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
| US5861164A (en) | 1989-03-21 | 1999-01-19 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
| US6207645B1 (en) | 1989-03-21 | 2001-03-27 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
| US5776459A (en) | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| US5614192A (en) | 1989-07-19 | 1997-03-25 | Connective Therapeutics, Inc. | T cell receptor peptides as therapeutics for immune-related disease |
| US5298396A (en) | 1989-11-15 | 1994-03-29 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying T cells disease involved in autoimmune disease |
| IL165071A (en) | 1990-03-30 | 2008-06-05 | Autoimmune Inc | A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients |
| AU8407091A (en) | 1990-07-06 | 1992-02-04 | Allergene, Inc. | Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
| US6083503A (en) | 1991-08-28 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection |
| US5480895A (en) | 1991-09-27 | 1996-01-02 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof |
| US5545716A (en) | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
| WO1994020120A1 (en) | 1993-03-12 | 1994-09-15 | Cellcor, Inc. | In vitro assay measuring degree of activation of immune cells |
| US5494899A (en) | 1993-04-07 | 1996-02-27 | Oklahoma Medical Research Foundation | Selective regulation of B lymphocyte precursors by hormones |
| IL108926A0 (en) | 1993-05-14 | 1994-06-24 | L Willems Instituut Dr | Human t cell monoclone, process for its production and its use for the treatment and diagnosis of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer |
| IL110787A0 (en) | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
| US5956058A (en) * | 1993-11-05 | 1999-09-21 | Seiko Epson Corporation | Ink jet print head with improved spacer made from silicon single-crystal substrate |
| US5552300A (en) | 1994-01-13 | 1996-09-03 | T Cell Sciences, Inc. | T cell antigen receptor V region proteins and methods of preparation thereof |
| US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
| US5723503A (en) | 1994-09-28 | 1998-03-03 | Thomas Jefferson University | Biological treatment for rheumatoid arthritis |
| US5674487A (en) | 1994-09-28 | 1997-10-07 | Univ Jefferson | Method for treating autoimmune diseases |
| US6033661A (en) | 1995-06-07 | 2000-03-07 | Thomas Jefferson University | Composition and method for allogenetic mononuclear cell immunotherapy |
| US6096314A (en) | 1994-10-07 | 2000-08-01 | Yeda Research And Development Co. Ltd. | Peptides and pharmaceutical compositions comprising them |
| AU721898B2 (en) | 1994-11-18 | 2000-07-20 | Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
| FR2727117A1 (fr) | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
| US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| US5874531A (en) | 1995-03-07 | 1999-02-23 | President And Fellows Of Harvard College | Identification of self and non-self antigens implicated autoimmune disease |
| US5869057A (en) | 1995-06-07 | 1999-02-09 | Rock; Edwin P. | Recombinant vaccines to break self-tolerance |
| SE9502921D0 (sv) | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
| US5739307A (en) | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
| US5716946A (en) | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
| CA2250361A1 (en) * | 1996-03-28 | 1997-10-02 | Barbara Wallner | Myelin oligodendrocyte glycoprotein peptides and uses thereof |
| US5750356A (en) | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
| US5849886A (en) | 1996-07-10 | 1998-12-15 | Oy Aboatech Ab | Extraction of myelin basic protein |
| US20010031253A1 (en) | 1996-07-24 | 2001-10-18 | Gruenberg Micheal L. | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
| US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
| JP2001509135A (ja) | 1996-10-11 | 2001-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 混合リンパ球と組み合わせた腫瘍細胞を用いるガン免疫療法 |
| US6054292A (en) | 1997-07-18 | 2000-04-25 | Incyte Pharmaceuticals, Inc. | T-cell receptor protein |
| US20020009448A1 (en) * | 1997-09-19 | 2002-01-24 | Leslie P. Weiner | T-cell vaccination for the treatment of multiple sclerosis |
| US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| US20020001841A1 (en) * | 1998-06-26 | 2002-01-03 | Keld Kaltoft | Continuous t-cell lines |
| EP1090299A1 (en) * | 1998-06-26 | 2001-04-11 | Biomira, Inc. | Methods of detecting t-cell activation |
| AU5906099A (en) | 1998-09-04 | 2000-03-27 | Baylor College Of Medicine | T cell peptides as therapeutics for immune-related disease |
| CA2362099C (en) * | 1999-02-23 | 2014-05-13 | Baylor College Of Medicine | T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| US6187750B1 (en) | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
| WO2001031021A1 (en) * | 1999-10-28 | 2001-05-03 | Universite De Geneve | Multiple sclerosis-related superantigen |
| US6746670B2 (en) | 2000-08-15 | 2004-06-08 | Schering Corporation | Regulatory T cells; methods |
| EP1311543A1 (en) | 2000-08-22 | 2003-05-21 | Baylor College Of Medicine | T cell receptor v beta-d beta-j beta sequence and methods for its detection |
| US7658926B2 (en) | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| JP2005536982A (ja) | 2001-11-07 | 2005-12-08 | 麒麟麦酒株式会社 | インビトロにおけるｔ細胞増幅および増幅されたｔ細胞集団 |
| US20050181459A1 (en) * | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| EP1546719B1 (en) * | 2002-08-08 | 2015-04-01 | Baylor College Of Medicine | Isolation and identification of t cells |
-
2003
- 2003-08-06 EP EP03784936.1A patent/EP1546719B1/en not_active Expired - Lifetime
- 2003-08-06 CA CA2492848A patent/CA2492848C/en not_active Expired - Fee Related
- 2003-08-06 RU RU2005106842/15A patent/RU2327487C2/ru not_active IP Right Cessation
- 2003-08-06 PT PT101822963T patent/PT2363710E/pt unknown
- 2003-08-06 PT PT37849361T patent/PT1546719E/pt unknown
- 2003-08-06 WO PCT/US2003/024548 patent/WO2004015070A2/en not_active Ceased
- 2003-08-06 EP EP10182296.3A patent/EP2363710B1/en not_active Expired - Lifetime
- 2003-08-06 US US10/524,300 patent/US7695713B2/en not_active Expired - Fee Related
- 2003-08-06 AU AU2003258090A patent/AU2003258090B2/en not_active Ceased
- 2003-08-06 PL PL374673A patent/PL214283B1/pl unknown
- 2003-08-06 MX MXPA05001044A patent/MXPA05001044A/es active IP Right Grant
- 2003-08-06 CN CNB038192349A patent/CN100567987C/zh not_active Expired - Fee Related
- 2003-08-06 ES ES10182296.3T patent/ES2545736T3/es not_active Expired - Lifetime
- 2003-08-06 NZ NZ537816A patent/NZ537816A/en not_active IP Right Cessation
- 2003-08-06 CA CA2759572A patent/CA2759572A1/en not_active Abandoned
- 2003-08-06 JP JP2004527772A patent/JP4705371B2/ja not_active Expired - Fee Related
- 2003-08-06 BR BRPI0305769A patent/BRPI0305769A8/pt not_active IP Right Cessation
- 2003-08-06 ES ES03784936.1T patent/ES2537951T3/es not_active Expired - Lifetime
- 2003-08-06 KR KR1020057001587A patent/KR100795840B1/ko not_active Expired - Fee Related
-
2005
- 2005-01-17 IL IL166332A patent/IL166332A/en not_active IP Right Cessation
- 2005-01-26 NO NO20050447A patent/NO338881B1/no not_active IP Right Cessation
- 2005-02-02 ZA ZA200500985A patent/ZA200500985B/xx unknown
-
2010
- 2010-02-23 US US12/711,160 patent/US20100239548A1/en not_active Abandoned
- 2010-04-21 JP JP2010098263A patent/JP2010178759A/ja active Pending
-
2015
- 2015-04-16 NO NO20150482A patent/NO20150482L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545736T3 (es) | Aislamiento e identificación de células T | |
| US7709257B2 (en) | Models for vaccine assessment | |
| Jagessar et al. | Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete freund adjuvant | |
| US11471517B2 (en) | Compositions and methods for preventing and treating graft versus host disease | |
| Batchelder et al. | Myeloid‐lymphoid ontogeny in the rhesus monkey (Macaca mulatta) | |
| ES2928879T3 (es) | Linfocitos citolíticos naturales | |
| US11567078B2 (en) | Blood cell biomarker for late onset Alzheimer's disease | |
| CN1845988B (zh) | 肿瘤免疫治疗的方法 | |
| Kaschula, VR*, Van Dellen, AF** & De Vos | Some infectious diseases of wild vervet monkeys (Cercopithecus aethiops pygerythrus) in South Africa | |
| Onoé et al. | Sequential changes of thymocyte surface antigens with presence or absence of graft-vs-host reaction following allogeneic bone marrow transplantation | |
| Sajic et al. | The role of CD8+ T cells in a model of multiple sclerosis induced with recombinant myelin oligodendrocyte glycoprotein | |
| Xie et al. | Induced immune tolerance of autoantigen loaded immature dendritic cells in homogenic lupus mice | |
| US20110252487A1 (en) | Composition for inducing th2 cell, therapeutic composition for th2-type disease, and use of same | |
| US20180153145A1 (en) | Humanized mice and uses thereof | |
| Sanchez | Investigating the role of T cells in Alzheimer’s Disease Pathogenesis | |
| ZOLLINGER et al. | Induction by thymic fractions of T cell subsets capable of modulating GvHr intensity | |
| Nishikawa et al. | PPD-Induced Immunoglobulin Production in Human Peripheral Blood Lymphocytes: II. Separation of PPD-Reactive Helper T Cells from PWM-Reactive Helper T Cells in Polyclonal Immunoglobulin Production of Human Peripheral Blood Lymphocytes | |
| Soromenho | Role of S100b in EAE Pathogenesis | |
| Ren | Characterizing Interleukin 21 in its role as the CD4 T cell help during mouse polyomavirus infection | |
| Thyagarajan | Contributions of GPCRs CCR8 and GALR2 to thymic central tolerance and thymic epithelial cell homeostasis | |
| Benet et al. | CCL3 promotes germinal center B cells sampling by follicular regulatory T cells and ensures optimal humoral response | |
| Matsuya et al. | NAOSITE: Nagasaki University's Academic Output SITE | |
| Robinson et al. | Caroline C. Chapman, Timothy L. Williams | |
| Wanjara | Delineating signaling mechanisms involved in lymphocyte chemotaxis, immune homeostasis and allergic asthma | |
| Mauermann | The opposing roles of Interferon-γ and IL-17 in inflammation |